$NVIV News
Last published 3y ago
- 3y agoNVIVInVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord InjuryBusiness WireStudy did not achieve primary endpoint of defined improvement on standard impairment scale InVivo to evaluate full data set and strategic options for the company InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a
- 4y agoNVIVInVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its
- 4y agoNVIVInVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a
- 4y agoNVIVInVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Offic
- 4y agoNVIVInVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General CounselBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Of
- 4y agoNVIVInVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed NeurosurgeryBusiness WireManuscript details patient outcomes through 24-month follow up visit InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) today announced the publication of a peer-reviewed manuscript in Neurosurgery describing the previously disclosed 12- and 24-month d
- 4y agoNVIVInVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury StudyBusiness WireTopline data expected to be reported in Q1 2023 InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has
- 4y agoNVIVInVivo Therapeutics Announces Reverse Stock SplitBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:
- 4y agoNVIVInVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect ConferenceBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Offic
- 5y agoNVIVInVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment ConferenceBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Offic
- 5y agoNVIVInVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury StudyBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury
- 5y agoNVIVPKICBMBioFlyte Forms Scientific Advisory Board of Prominent Government and Life Science ExpertsBusiness WireIndustry leaders with experience from The Pentagon, PerkinElmer, Johns Hopkins and more will help advance BioFlyte's mission to bring biological mass spectrometry to the field BioFlyte, a biodetection company with a revolutionary new class of fieldab
- 5y agoNVIVInVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company's Complete HDE SubmissionBusiness WireInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the acceptance by the U.S. Food and Drug Administration (FDA) o
- 5y agoNVIVInVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021Business WireCalls for All Stockholders to Vote and to Vote in Favor of the Proxy Proposals InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injurie
- 5y agoNVIVInVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, w ...
- 5y agoNVIVInVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is schedu ...
- 5y agoNVIVInVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: SpineBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's single-arm INSPIRE 1.0 study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and N ...
- 6y agoNVIVInVivo Therapeutics Announces Closing of $15.0 Million Public OfferingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $0.80 per sha ...
- 6y agoNVIVInVivo Therapeutics Announces Pricing of $15.0 Million Public OfferingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $ 0.80 per share (or pre-funded warrant) and ...
- 6y agoNVIVInVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is s ...
- 6y agoNVIVInVivo Therapeutics Announces Closing of $7.0 Million Public OfferingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 2,545,455 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of $2.75 per share (or ...
- 6y agoNVIVInVivo Therapeutics Announces Reverse Stock SplitBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-30 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on February 11, 2020, and shares of InVivo Therapeutics common stock will trade on a post- ...
- 6y agoNVIVInVivo Therapeutics Announces Closing of Public Offering of Common StockBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the closing of its previously announced public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are $840,000, before deducting the fees and estimated offering expenses payable by InVivo ...
- 6y agoNVIVInVivo Therapeutics Announces Pricing of Public Offering of Common StockBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the pricing of a public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are expected to be $840,000, before deducting the fees and estimated offering expenses payable by InVivo Therape ...
- 6y agoNVIVInVivo Therapeutics Announces Proposed Public Offering of Common StockBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced that it has commenced a proposed public offering of shares of its common stock, par value $0.00001 per share. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms ...
- 7y agoNVIVInVivo Therapeutics Announces Publication of CONTEMPO Registry Study Data in Peer-Reviewed Journal Spinal CordBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a manuscript in the peer-reviewed journal Spinal Cord describing its CONTEMPO registry study data. The CONTEMPO registry study, part of the Company’s IDE submission for the Neuro-Spinal Scaffold™, was designed to provide comprehensive natural history benchmarks for the Neuro-Spin ...
- 7y agoNVIVInVivo Therapeutics Announces Postponement of Annual MeetingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has postponed its 2019 annual meeting of stockholders. The annual meeting, which was originally scheduled for June 11, 2019, had been adjourned until July 11, 2019 at 8:00 am Eastern Time. Less than a majority of the shares of the Company’s outstanding common stock entitled to vote at the m ...
- 7y agoNVIVInVivo Therapeutics gibt Vertagung der Hauptversammlung bekanntBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) gab heute bekannt, dass die am 11. Juni 2019 einberufene Hauptversammlung 2019 ohne Abhandlung geschäftlicher Fragen wieder vertagt wurde, da die Beschlussfähigkeit nicht gegeben war. Die Hauptversammlung wird am 2. Juli 2019 wiederholt, um den Aktionären eine bessere Gelegenheit zur Abstimmung über alle Vorschläg ...
- 7y agoNVIVInVivo Therapeutics Announces Adjournment of Annual MeetingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that its 2019 Annual Meeting of Stockholders, scheduled for June 11, 2019, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Annual Meeting will be reconvened July 2, 2019 to allow more opportunity for stockholders to vote on all propo ...